Hims & Hers Health is partnering with Novo Nordisk to expand access to FDA-approved GLP-1 weight loss medications through its U.S. platform.
The agreement includes Ozempic injections in 0.5-, 1- and 2-milligram doses, as well as Wegovy injections in 1.7- and 2.4-milligram doses and Wegovy tablets in 1.5-, 4-, 9- and 25-milligram strengths, according to a March 9 news release. The products will be available later this month.
Hims & Hers said it will stop advertising compounded GLP-1 offerings and limit access to those medications to patients for whom FDA-approved alternatives are not clinically appropriate.
The partnership follows a legal dispute between the companies. In early February, Hims & Hers began selling a compounded version of Novo’s newly approved Wegovy pill for $99 per month. Novo filed a patent infringement lawsuit the same day, and HHS referred the company to the Justice Department over potential violations of federal drug law. Hims & Hers removed the product days later.
Novo is now dismissing its lawsuit without prejudice. The partnership revives a 2025 collaboration that dissolved within months amid disagreements over compounded drugs.
FDA Commissioner Marty Makary, MD, congratulated both parties March 9 on X, saying the deal maintains affordable pricing, limits compounded drugs to FDA-compliant cases, and follows recent action by the agency. He called the outcome “a win for the American people.”
